Clinical Proof of concept for a RNA-targeting Oligonucleotide for a Cystic fibrosis-F508del MEDication

Informations projet

PRO-CF-MED

N° de convention de subvention: 633545

DOI 10.3030/633545

Projet clôturé

Date de signature de la CE 21 Avril 2015

Date de début 1 Mai 2015

Date de fin 31 Decembre 2017

Financé au titre de

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Coût total € 21 237 179,50

Contribution de l’UE € 5 997 139,00

Coordonné par

PROQR THERAPEUTICS NV
Netherlands

Livrables

Websites, patent fillings, videos etc. (1)

PRO-CF-MED project website developed including project updates and patient ‘friendly’ section

Publications

Other (1)

QR-010 significantly improves CFTR function in nasal potential difference proof of concept study in subjects with CF homozygous for the F508del-CFTR mutation

Auteurs: I Sermet-Gaudelus, D Nichols, JA Nick, C De Boeck, JP Clancy, GM Solomon, SM Rowe, JS Elborn, MA MAll, JA Bolognese, F Bouisset, W den Hollander, N Lamontagne, N Tomkinson, N Henig
Publié dans: 2016
Éditeur: poster at the North American Cystic Fibrosis Conference

Peer reviewed articles (1)

Cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis: current perspectives

Auteurs: Sabrina Noel, Bela Z Schmidt, Jeremy Haaf, Teresinha Leal
Publié dans: Clinical Pharmacology: Advances and Applications, Numéro Volume 8, 2016, Page(s) 127-140, ISSN 1179-1438
Éditeur: Dove Medical Press Ltd
DOI: 10.2147/CPAA.S100759

Droits de propriété intellectuelle

Patent (1)

OLIGONUCLEOTIDES FOR MAKING A CHANGE IN THE SEQUENCE OF A TARGET RNA MOLECULE PRESENT IN A LIVING CELL

Numéro de demande/publication: EP 13760133
Date: 2013-07-12
Demandeur(s): PROQR THERAPEUTICS NV